EIF3c: A potential therapeutic target for cancer

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 158-166

  Emmanuel, Rafi ^a   Weinstein, Shiri ^a   Landesman Milo, Dalit ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

EIF3; EIF3c; Lipid based nanoparticles; RNAi; Translation

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; EUKARYOTIC TRANSLATION INITIATION FACTOR 3 SUBUNIT C GENE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RNA INTERFERENCE;

ANIMALS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EUKARYOTIC INITIATION FACTOR-3; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HELA CELLS; HUMANS; MCF-7 CELLS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EUKARYOTA;

EID: 84878958676     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.04.026     Document Type: Article

References (21)

1. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
2. Jackson R.J. Alternative mechanisms of initiating translation of mammalian mRNAs. Biochem. Soc. Trans. 2005, 33:1231-1241.
3. W.L. Chiu, S. Wagner, A. Herrmannova, L. Burela, F. Zhang, A.K. Saini, L. Valasek, A.G. Hinnebusch, The C-terminal region of eukaryotic translation initiation factor 3a (eIF3a) promotes mRNA recruitment, scanning, and, together with eIF3j and the eIF3b RNA recognition motif, selection of AUG start codons, Mol. Cell Biol. 30:4415-4434.
4. Sizova D.V., Kolupaeva V.G., Pestova T.V., Shatsky I.N., Hellen C.U. Specific interaction of eukaryotic translation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. J. Virol. 1998, 72:4775-4782.
5. Hinnebusch A.G. EIF3: a versatile scaffold for translation initiation complexes. Trends Biochem. Sci. 2006, 31:553-562.
6. Masutani M., Sonenberg N., Yokoyama S., Imataka H. Reconstitution reveals the functional core of mammalian eIF3. EMBO J. 2007, 26:3373-3383.
7. Zhou M., Sandercock A.M., Fraser C.S., Ridlova G., Stephens E., Schenauer M.R., Yokoi-Fong T., Barsky D., Leary J.A., Hershey J.W., Doudna J.A., Robinson C.V. Mass spectrometry reveals modularity and a complete subunit interaction map of the eukaryotic translation factor eIF3. Proc. Natl. Acad. Sci. USA 2008, 105:18139-18144.
8. C. Sun, A. Todorovic, J. Querol-Audi, Y. Bai, N. Villa, M. Snyder, J. Ashchyan, C.S. Lewis, A. Hartland, S. Gradia, C.S. Fraser, J.A. Doudna, E. Nogales, J.H. Cate, Functional reconstitution of human eukaryotic translation initiation factor 3 (eIF3), Proc. Natl. Acad. Sci. USA 108:20473-20478.
9. M. Karaskova, S. Gunisova, A. Herrmannova, S. Wagner, V. Munzarova, L. Valasek, Functional characterization of the role of the N-terminal domain of the c/Nip1 subunit of eukaryotic initiation factor 3 (eIF3) in AUG recognition, J. Biol. Chem. 287:28420-28434.
10. Zhang L., Pan X., Hershey J.W. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J. Biol. Chem. 2007, 282:5790-5800.
11. Rothe M., Ko Y., Albers P., Wernert N. Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am. J. Pathol. 2000, 157:1597-1604.
12. Scoles D.R., Yong W.H., Qin Y., Wawrowsky K., Pulst S.M. Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum. Mol. Genet. 2006, 15:1059-1070.
13. Johannes G., Sarnow P. Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. RNA 1998, 4:1500-1513.
14. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319:627-630.
15. D. Landesman-Milo, M. Goldsmith, S. Leviatan Ben-Arye, B. Witenberg, E. Brown, S. Leibovitch, S. Azriel, S. Tabak, V. Morad, D. Peer, Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells, Cancer Lett.
16. K. Theilgaard-Monch, J. Boultwood, S. Ferrari, K. Giannopoulos, J.M. Hernandez-Rivas, A. Kohlmann, M. Morgan, B. Porse, E. Tagliafico, C.M. Zwaan, J. Wainscoat, M.M. Van den Heuvel-Eibrink, K. Mills, L. Bullinger, Gene expression profiling in MDS and AML: potential and future avenues, Leukemia 25:909-920.
17. A. Daka, D. Peer, RNAi-based nanomedicines for targeted personalized therapy, Adv. Drug Deliv. Rev. 64:1508-1521.
18. R. Elfakess, D. Peer, Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles, IDrugs 13:626-631.
19. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
20. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. J. Biol. Chem. 2000, 275:26967-26975.
21. S. Misra, P. Heldin, V.C. Hascall, N.K. Karamanos, S.S. Skandalis, R.R. Markwald, S. Ghatak, Hyaluronan-CD44 interactions as potential targets for cancer therapy, FEBS J 278:1429-1443.